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2DNA double-strand breaks (DSBs) are perhaps the most toxic of all DNA lesions,
with defects in the DNA damage response to DSBs being associated with various
human diseases. Although it is known that DSB repair pathways are tightly
regulated by ubiquitylation, we do not yet have a comprehensive understanding
of how deubiquitylating enzymes (DUBs) function in DSB responses. Here, by
carrying out a multi-dimensional screening strategy for human DUBs, we
identify several with hitherto unknown links to DSB repair, the G2/M DNA-
damage checkpoint and genome-integrity maintenance. Phylogenetic analyses
reveal functional clustering within certain DUB subgroups, suggesting
evolutionally conserved functions and/or related modes-of action. Furthermore,
we establish that the DUB UCHL5 regulates DSB resection and repair by
homologous recombination through protecting its interactor, NFRKB, from
degradation. Collectively our findings extend the list of DUBs promoting the
maintenance of genome integrity, and highlight their potential as therapeutic
targets for cancer.
Genomic DNA in all organisms is exposed to various endogenously-generated and
exogenous DNA damaging agents, including ultra-violet light, reactive oxygen
species, ionizing radiation (IR) and chemotherapeutic medicines. These agents
generate DNA lesions that threaten genome integrity by compromising normal DNA-
based processes such as replication, transcription and cell division. To mitigate the
deleterious effects of DNA lesions, specialized DNA repair mechanisms have
evolved, whose loss or deregulation causes cancer and various hereditary diseases
1
. In
eukaryotic cells, DNA double-strand breaks (DSBs), perhaps most toxic DNA lesions,
are mainly repaired by homologous recombination (HR) or non-homologous end
3joining (NHEJ)
2
. DSBs also trigger intracellular signaling processes termed the DNA-
damage response (DDR), which includes cell-cycle checkpoint arrest responses. It is
well known that DSB repair and associated events are tightly regulated by post-
translational protein modifications. For instance, protein phosphorylation plays key
roles in DSB repair and DDR signaling via the actions of protein kinases such as
DNA-PK, ATM, ATR, CHK1 and CHK2
3-5
. Furthermore, it has become apparent that
ubiquitylation – the covalent attachment of the 76 amino-acid residue protein,
ubiquitin, to target molecules – also plays important roles in controlling DSB repair
and DDR processes
6
. Ubiquitylation is a sequential enzymatic reaction mediated by
E1, E2 and E3 enzymes, resulting in mono- or poly-ubiquitylation involving the use
of seven lysine residues (K6, K11, K27, K29, K33, K48, and K63) on ubiquitin as
well as the ubiquitin amino terminus
7
. The classical function of ubiquitylation, mainly
via K48 linked chains, is to target substrates to proteasome dependent degradation.
However, it is now clear that other types of poly-ubiquitylation as well as mono-
ubiquitylation also play other prevalent roles through regulating protein interactions,
activity and subcellular localisation
8
.
In many instances, ubiquitylation is regulated by its removal through the actions of
specific deubiquitylating enzymes (DUBs), some of which also play key roles in
ubiquitin-precursor processing
9
. The human genome encodes 94 potential DUBs that
can be divided into five subfamilies based on sequence and structural features of their
catalytic domains: ubiquitin-specific proteases (USPs), ubiquitin carboxyl-terminal
hydrolases (UCHs), ovarian tumor proteases (OTUs), Machado-Joseph disease
enzymes (MJDs) and JAB1/MPN/MOV34 metalloenzymes (JAMMs)
10
. While
various DUBs have been connected to DDR processes
11-18
, an important challenge is
4to achieve a more comprehensive understanding of DUB functions in this context.
Here, to address this challenge, we have systematically characterized human DUBs
for roles in DSB repair, the DNA-damage induced G2/M cell cycle checkpoint and
the overt maintenance of genome integrity. In addition to identifying many DUBs
with DDR roles, this work also lead to establish that one, UCHL5 promotes DSB end
resection and HR through regulating the stability of the NFRKB protein that is a
subunit of chromatin remodeling complex INO80.
RESULTS
Primary screens for DUBs promoting the DDR or the G2/M DNA-damage
checkpoint
To identify DUBs with DSB-responsive roles, we carried out systematic screens
employing three different techniques (Fig. 1). First, after cloning the coding regions
for 71 of the 94 human DUBs into vectors to express them fused to green fluorescent
protein (GFP) in human U2OS cells, we used live-cell imaging to examine each GFP-
DUB fusion for recruitment to DNA damage sites generated by laser micro-
irradiation, a technique commonly used to measure DSB-responses (Supplementary
Table 1)
19
. In a parallel primary screen, we employed 90 short-interfering RNA
(siRNA) pools to individually deplete each of the corresponding DUBs in human
U2OS cells. Ensuing DUB-depleted cells and control cells were then treated with the
DSB-generating reagent phleomycin, and cell extracts were analyzed by
immunoblotting for canonical DSB-induced phosphorylations on CHK1 Ser-345,
CHK2 Thr-68 and histone H2AFX (also known as H2AX) Ser-139 (γH2AX). In
parallel, the effect of depleting all human DUBs on the G2/M DNA-damage
5checkpoint was assessed by quantifying the mitotic mark, phosphorylated histone H3
Ser-10, before and after DNA damage induction by phleomycin (Fig. 1 and Fig. 2a).
This work identified 17 DUBs, whose depletion caused persistence of phosphorylated
H3 Ser-10 after DNA damage induction (Fig. 2a) to a degree greater than two-times
(green) or three-times (red) the standard deviation of the siRNA control. This thereby
suggested these DUBs as playing roles in cell-cycle progression or G2/M checkpoint
control (for identities of these DUBs, see Supplementary Table 1). We note that this
aspect of our work identified several DUBs (CSN5, USP19 and USP37) that had been
previously linked to the G2/M checkpoint, thereby providing validation of our
screening methodology
20-23
. Moreover, our DNA-damage localisation and DDR
signaling screens collectively identified 44 DUBs as candidates for affecting the DDR
following DSB induction (Fig. 1 and Supplementary Table 1).
Identifying DUBs involved in DSB repair and/or genome integrity maintenance
To further examine whether the 44 DDR-DUB candidates we identified were
involved in maintaining genome stability and/or DSB repair, we used siRNA pools to
deplete them, then used neutral comet assays (Fig. 1 and see METHODS) to directly
measure DSBs in cells that had or had not been exposed to phleomycin. Importantly,
by employing siRNA-mediated depletion of BRCA1 and XRCC4, which play
important roles in HR and NHEJ, respectively, we established that defects in either of
these DSB repair pathways can be detected by the comet assay (Fig. 2b). This work
indicated that depleting each of ten DUBs (USP44, PSMD14, USP26, MYSM1,
OTUD6B, USP5, USP49, JOSD1, USPL1 and USP1) resulted in DSB induction even
without exposing cells to phleomycin (Fig. 2c and Supplementary Table 1),
6suggesting functions for these DUBs in replication and/or repairing endogenously
generated DNA damages that can become converted to DSBs during replication.
Moreover, these comet-assay screens identified 23 DUBs whose depletion resulted in
a DSB repair defect greater than two times the standard deviation of the siRNA
control (Fig. 2b and also see Fig. 4a). These included USP1, USP3, USP5, USP7,
USP11, BAP1 and BRCC3 (BRCC36), which have previously-suggested DDR
connections
11-18
, thereby indicating that our screen identified DUBs with positive
roles in DSB repair. On the other hand, we also found 13 DUBs that were recruited to
DNA damage sites but gave only marginal DSB repair defects upon siRNA depletion,
including OTUB1, a negative regulator of the UBE2N (UBC13) ubiquitin E2
enzyme
24
, USP44 that is reported to antagonize RNF168 dependent ubiquitylation
25
,
and OTUB2 that functions in repair-pathway choice
26
(Fig. 2b, Fig. 3a, and Fig. 4a),
suggesting that some of the additional DUBs we identified might be negative DDR
regulators and/or be involved in repair-pathway choice. Interestingly, phylogenetic
analysis of the DUBs that we identified with associations to DSB repair (Fig. 3b) or
G2/M checkpoint control (Fig. 3c) revealed clustering in certain DUB subgroups (for
instance in Fig. 3b, the entire UCH subclass and those containing USP5 and USP13,
USP11 and USP15, or BRCC3 and CSN5). This suggests that these DUBs might have
overlapping functions and/or related modes-of-action in DSB-responses.
To extend our analyses further, we selected the ten highest scoring DUBs from the
DSB-repair secondary screen and assessed the impacts of their depletion with
individual siRNAs in neutral comet assays (Fig. 4a, b; active individual siRNAs were
deconvoluted from the siRNA pools through assessing their target DUBs by
immunoblotting; data not shown). This work identified six DUBs (USP7, USP13,
7USP15, USP20, CSN5 and UCHL5) whose depletion yielded significant and
reproducible DSB repair defects in neutral comet assays (Fig. 4b). Moreover, we
carried out clonogenic survival assays to establish the effect of depleting these DUBs
on cellular sensitivity to ionizing radiation (IR). This revealed that depletion of each
of these DUBs resulted in significant IR hypersensitivity, demonstrating that our
screen effectively identified DUBs with positive roles in DSB repair (Fig. 4a-c and
Fig. 5a; note that USP11 depletion, which we had found to result in a DSB repair
defect in the comet assay, also caused mild IR hypersensitivity, consistent with a
previous report linking it to the DDR
17
). Although it will be worthwhile pursuing
DDR functions for all of these DUBs as well as others identified as putative DDR
regulators by our screens, we focused our further analyses on UCHL5 (ubiquitin
carboxyl-terminal hydrolase L5; also known as UCH37). This protein was prioritized
because it was the only DUB other than the deneddylase CSN5 that was positive in all
three of our screening assays (localisation, DDR signaling and DSB repair) and
because we found that depleting each member of human UCH DUB family resulted in
DSB repair defects (Fig. 3b and Fig. 4a).
UCHL5 promotes HR and extensive DNA-end resection
As shown in Figure 5a, we found that UCHL5 depletion rendered cells hypersensitive
to IR in clonogenic survival assays, producing similar sensitivity as that caused by
depleting BRCA1, a well-characterized HR factor. On further investigation, we
observed no effect of UCHL5 depletion on NHEJ as assessed by random plasmid
integration (Fig. 5b). By contrast, depleting UCHL5 with three distinct siRNAs lead
to significant impairments in HR repair efficiencies as measured by a chromosomal
DSB-induced gene-conversion assay system (Fig. 5c; as shown in Supplementary Fig.
81a, this was not associated with potentially confounding changes in cell-cycle
profiles). Furthermore, in accordance with an HR defect, depletion of UCHL5
resulted in hypersensitivity to camptothecin, which stabilizes topoisomerase I
cleavage-complexes, leading to DNA replication-dependent DSBs in S-phase that are
repaired by HR-mediated mechanisms (Supplementary Fig. 1b). To determine
whether these defects were indeed due to UCHL5 depletion, we established stable cell
lines expressing GFP alone or GFP-tagged UCHL5 (GFP-UCHL5; Supplementary
Fig. 1c). These cells were treated with a control siRNA, an siRNA targeting both
endogenous UCHL5 and the GFP-UCHL5 construct, or an siRNA against the UCHL5
3’ untranslated region (3’-UTR) to target endogenous UCHL5 but not GFP-UCHL5
(Fig. 5d). Importantly, the effects of endogenous UCHL5 depletion on phleomycin-
induced DSB repair were rescued by expressing GFP-UCHL5 wild-type (WT) but not
by expressing a GFP-UCHL5 construct (deubiquitylase dead; DD)
27
lacking
deubiquitylase activity because Cys-88 was replaced by Ala (Fig. 5d and
Supplementary Fig. 1c). This was despite GFP-UCHL5 DD being recruited to sites of
damage as efficiently as GFP-UCHL5 WT (Fig. 5e). Taken together, these data
supported a model in which UCHL5 is recruited to sites of DNA damage, where its
deubiquitylase activity then promotes DSB repair.
To gain insights into how UCHL5 promotes DSB repair, we examined the effect of its
depletion on DDR signaling following camptothecin treatment. This revealed that
UCHL5 depletion impaired phosphorylation of replication protein A subunit 2
(RPA2) on Ser4/Ser8 (Fig. 6a). Since RPA2 Ser4/Ser8 phosphorylation defects
correlate with compromised DNA-end resection
28,29
, we assessed single-stranded
DNA (ssDNA) production after camptothecin treatment. This revealed that ssDNA
9focus formation was reduced, although still detectable, upon UCHL5 depletion
(Supplementary Fig. 1d). To quantify ssDNA formation, we established a flow-
cytometry based method to measure the signal intensity of native anti-BrdU staining
in cells after camptothecin treatment (see METHODS). Thus, we found that UCHL5
depletion reduced resection of camptothecin-induced DSBs to a similar extent as that
caused by depleting the end-resection factors EXO1 or BLM (Fig. 6b). Furthermore,
while UCHL5 depletion did not abolish camptothecin-induced RPA focus production
(Supplementary Fig. 1e, f), the intensities of RPA on ssDNA were reduced (Fig. 6c).
UCHL5 depletion also reduced camptothecin-induced focus formation by the key HR
factor RAD51, a phenotype rescued by wild-type UCHL5 but not by catalytically
inactive UCHL5 (Supplementary Fig. 1g and data not shown). Furthermore, the
camptothecin-induced RPA2 phosphorylation defect caused by UCHL5 depletion was
rescued by wild-type but not catalytically inactive UCHL5 (Fig. 6d, e). Collectively,
these data suggested that UCHL5 is dispensable for initiation of DNA-end resection
but is important for the full resection process.
To define which step(s) leading to DNA-end resection was affected by UCHL5, we
examined the DNA-damage recruitment of various factors linked to resection.
Although, depleting UCHL5 had no marked effect on GFP-CtIP accumulation at
damage sites (Fig. 6f and Supplementary Fig. 1h), it significantly impaired GFP-
EXO1 recruitment (Fig. 6g). These observations implied that UCHL5 functions prior
to EXO1 but after CtIP to promote resection and ensuing HR. To examine whether
UCHL5 regulates extensive resection pathways involving BLM and possibly DNA2,
we carried out assays in cells depleted for various resection factors. Since additive
effects were observed when UCHL5 was co-depleted with either EXO1 or BLM
10
(Supplementary Fig. 1i), this suggested that UCHL5 affects both EXO1- and BLM-
dependent resection processes.
UCHL5 affects HR repair apart from its function as a proteasome component
Because UCHL5 is a subunit of the proteasome 19S regulatory particle lid
27,30-32
, and
since proteasome inhibition causes defective DSB-induced RPA2
phosphorylation
33,34
, we considered whether UCHL5 depletion might affect resection
and HR via causing general proteasome dysfunction. However, we found that while
treating cells with the proteasome inhibitor MG132 resulted in significant
accumulation of ubiquitylated proteins, this did not occur upon UCHL5 depletion
(Supplementary Fig. 2a). Moreover, although 53BP1 focus formation after IR was
inhibited by MG132 treatment or depletion of the DDR ubiquitin E3 ligase RNF8
35-
37
, it was not affected by UCHL5 depletion (Supplementary Fig. 2b). Furthermore,
although MG132 treatment strongly inhibited camptothecin-induced DNA-end
resection (Supplementary Fig. 2c), depletion of hRPN13 (ADRM1), which recruits
UCHL5 to the proteasome and enhances in vitro UCHL5 deubiquitylating activity
27
,
had only marginal effects on resection and accumulation of ubiquitylated proteins
(Supplementary Fig. 2d,e), suggesting that the role of UCHL5 in resection is distinct
from its proteasomal function
30,31
. While these findings did not exclude a possible
DSB repair function of UCHL5 in association with the proteasome, they suggested
that UCHL5 might affect resection and HR through additional mechanisms.
UCHL5 aids resection by protecting NFRKB from proteasomal degradation
Previous work has established that UCHL5 is a component of both the proteasome
and the INO80 chromatin remodeling complex; these complexes being mediated via
11
UCHL5 interactions with hRPN13 and NFRKB (nuclear factor related to κB-binding
protein), respectively (Supplementary Fig. 3a)
30,31,38
. We found that UCHL5
depletion reduced the steady-state level of NFRKB but not hRPN13 (Fig. 7a and data
not shown); and time-course studies in cells treated with cycloheximide, to prevent de
novo protein synthesis, revealed that UCHL5 depletion reduced NFRKB protein half-
life (Fig. 7b). UCHL5 depletion did not, however, reduce NFRKB mRNA levels, nor
protein levels of other INO80-complex subunits with suggested roles in DSB repair
(Supplementary Fig. 3b, c)
39-42
. Furthermore, NFRKB reduction caused by UCHL5
depletion was rescued in cells expressing GFP-UCHL5 and was prevented by MG132
treatment (Fig. 7c and Supplementary Fig. 3d). During these studies, we observed that
when cells were incubated with MG132, NFRKB in the chromatin fraction was
modified in a manner enhanced by UCHL5 depletion, suggestive of ubiquitylation
(Supplementary Fig. 3d). In addition, immunoprecipitation and western blotting
studies established that GFP-NFRKB but not GFP alone was conjugated with
ubiquitin moieties in the chromatin fraction (Fig. 7d; for controls, see Supplementary
Fig. 3e, f). Also, we found that purified UCHL5 could act to remove ubiquitylations
on NFRKB and/or associated proteins in vitro (Supplementary Fig. 3g). Taken
together, these findings suggested that UCHL5 removes ubiquitin chains to protect
NFRKB from proteasomal degradation.
Consistent with a model in which the effects of UCHL5 on DSB repair reflect it
stabilizing NFRKB, we found that, as with UCHL5 depletion, NFRKB depletion
reduced DNA-end resection in a manner complemented by a GFP-NFRKB expression
construct that was resistant to a 3’UTR-targeting siRNA (Fig. 7e and Supplementary
Fig. 4a). In addition, as observed for UCHL5 depletion, NFRKB depletion reduced
12
the intensity but not the proportion of cells with camptothecin-induced RPA foci
(Supplementary Fig. 4b-d). Furthermore, NFRKB depletion decreased HR efficiency
in cells as examined by a modified “traffic light reporter system” (see METHODS),
RAD51 focus formation, IR resistance and camptothecin-induced RPA2 Ser4/Ser8
phosphorylation (Fig. 7f, g and Supplementary Fig. 4e, f), without markedly affecting
cell cycle profiles or levels of the HR proteins XRCC3 and RAD54B
41
(Supplementary Fig. 4g, h). In accord with these findings, co-depleting NFRKB and
UCHL5 had similar effects on resection as their individual depletions (Fig. 7h and
Supplementary Fig. 4i). Importantly, we found that depleting INO80 chromatin
remodeling complex core subunits INO80, YY1 or RUVBL1 (which are responsible
for in vitro nucleosome remodeling activity of the complex
43
) also resulted in
defective resection, HR repair efficiency, IR resistance and RPA2 phosphorylation
(Fig. 7i, f, g and Supplementary Fig. 4j). Also, we found that NFRKB depletion or
YY1 depletion reduced the recruitment of EXO1 to DNA damage sites, but had no
discernible effect on GFP-CtIP recruitment (Supplementary Fig. 4k and data not
shown). These findings therefore suggested that NFRKB contributes to DNA-end
resection as a part of the INO80 chromatin remodeling complex, and support a model
in which the functions of UCHL5 in DSB resection and repair are specifically
connected to its role in stabilizing NFRKB. During the course of our studies, we
observed that NFRKB protein levels were reduced somewhat upon camptothecin
treatment, in a manner that was largely prevented by proteasome inhibition (Fig. 7j),
suggesting that although it promotes resection and HR (Fig. 7e, f), NFRKB may
undergo proteasome-dependent degradation/turnover after DSB induction.
Interestingly, immunoprecipitation studies from MG132-treated cells revealed that
NFRKB interacted with UCHL5 less in the chromatin fraction than in the
13
nucleoplasm, despite its interactions with INO80 being essentially equivalent in these
two fractions (Fig. 7k; for input fractions, see Supplementary Fig. 4l). Collectively,
these results suggested that ubiquitylation and degradation/turnover of NFRKB are
regulated by dynamic, chromatin-compartment specific interactions with UCHL5 that
are affected by DNA-damage induction, perhaps as a mechanism to prevent excessive
ssDNA formation at DNA damage sites.
DISCUSSION
Through carrying out focused, multi-faceted systematic functional screening, we have
identified DUBs that are recruited to or excluded from DNA-damage regions, as well
as DUBs whose depletion affects G2/M checkpoint control, DSB induction, DSB
repair and/or DSB-induced DDR signaling. In addition to identifying DUBs with
already-established links to DDR processes, our findings have indicated DDR
functions for DUBs that had not hitherto been connected to such events. This work
thus provides a resource that will be of value in future studies to define DDR and
potentially other functions for DUBs and their targets. Highlighting this potential, by
studying one DUB arising from our screens, UCHL5, we have established that it
functions to modulate the stability of the NFRKB component of the INO80 complex
to promote HR through enhancing the key process of DNA-end resection,
downstream of CtIP and at the level of EXO1 recruitment. While an involvement of
the INO80 complex in DSB repair has been reported in yeast
44
, and although studies
in mammalian cells have connected the INO80 complex to resection
39,40,42,45
, it was
not known how this occurs and whether the INO80 complex directly contributes to
resection rather than affecting this indirectly through its roles in transcription. We
have revealed that UCHL5 and NFRKB, non-essential for the in vitro nucleosome
14
sliding activity of the INO80 complex
43
and not conserved in yeast, enhance resection
by regulating the recruitment of the resection factor EXO1. This suggests that UCHL5
and NFRKB have acquired INO80-related functions in higher eukaryotes to promote
and control resection in the context of higher-order chromatin or other chromatin
features distinct from those found in simpler organisms. It will therefore be
worthwhile exploring whether UCHL5 and INO80 control resection and HR in more
compact regions of chromatin that may be recalcitrant to HR processes
46
. Given that
UCHL5 depletion also resulted in moderately reduced phosphorylation of H2AX in
addition to CHK1 in our immunoblotting screens, it will also be interesting to
investigate whether UCHL5 and the INO80 complex have roles in the DDR in
addition to their HR-related functions. Finally, we note that developing small-
molecule inhibitors of UCHL5, or other DUBs highlighted by our screens as having
DDR functions, might provide opportunities for therapeutic targeting of cancers
exhibiting high levels of DNA damage or which have underlying defects in DDR
processes or chromatin components.
METHODS
Methods and any associated references are available in the online version of the
paper.
Note: Supplementary Information is available in the online version of the paper.
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Figure legends
Figure 1 Screen to identify DUBs connected to DSB repair or the DNA damage
G2/M checkpoint.
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Schematic representation of the screen for human DUBs involved in DSB responses.
In the primary screen, GFP-fused DUB constructs were transfected into cells stably
expressing RFP-fused 53BP1, then localisation of GFP-DUBs to sites of DNA
damage induced by laser micro-irradiation was examined. In parallel, each DUBs was
depleted by siRNA pools and subjected to immunoblotting analysis for DDR or G2/M
checkpoint markers. In the secondary screen, 44 DUBs obtained from the primary
screen were subjected to neutral comet assay after depletion of each DUBs by siRNA
pools.
Figure 2 Classification of screen results.
(a) Results of screen for DUBs involved in G2/M DNA-damage checkpoint. Ratio of
signal intensity of phosphorylated histone H3 Ser-10 (H3 pS10) normalized to total
histone H3 level before and after damage (phleomycin 40 g/ml, 2 h) is plotted. Each
DUB is numbered in ascending order based on the H3 pS10 level, with the names of
the corresponding DUBs provided in Supplementary Table 1. Data shown is the one
experiment carried out for each DUB depletion and the mean of ten experiments for
siRNA control. Numbers 74-90, which are coloured with green or red, are: CSN6,
STAMBP, USP6, HINL1, USP8, EIF3S3, USP52, UCHL1, CSN5, USP20, USP49a,
USP19, USPL1, PSMD14, USP29, UCHL3 and USP37. (b) Results of DSB repair
secondary screen with indicated DUB siRNAs. Repair efficiencies were determined
by the tail moment ratio between 2 h after phleomycin (40 g/ml) removal (recovery)
and immediately after treatment (damaged) Data show the means of two (DUB,
XRCC4 and BRCA1 depletions) or seven (siRNA control depletions) biologically
independent experiments for respectively. (a, b) Two and three times standard
deviation of siRNA control (2 x and 3 x SD, respectively) are indicated. Depletion of
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XRCC4 and BRCA1 are supplied as positive controls. (c) Tail moments (arbitrary
unit: AU) of cells transfected with indicated siRNAs without exogenous DNA-
damage were plotted. Data show the means of two (DUB, XRCC4 and BRCA1
depletions) or seven (siRNA control) biologically independent experiments
respectively. One times standard deviation of siRNA control is indicated by
horizontal blue line.
Figure 3 Classification of DUBs based on localisation, DSB repair defects and
phylogenetic analysis
(a) Classification of screen results based on localisation of GFP-DUBs to laser micro-
irradiation sites and effects on DSB repair using siRNA pools (neutral comet assay).
DUBs in bold represent DUBs with previously reported connections to the DDR. *:
USP42 that was excluded from sites of DNA damage. **: not tested for localisation.
(b, c) Phylogenetic analysis of human DUBs for (c) DSB repair or (d) G2/M
checkpoint. DUBs are coloured green or red based on a degree of defect as shown in a
and b. Human DUBs are classified into five subfamilies; ubiquitin-specific proteases
(USPs), ubiquitin carboxyl-terminal hydrolases (UCHs), ovarian tumor proteases
(OTUs), Machado-Joseph disease enzymes (MJDs) and JAB1/MPN/MOV34
metalloenzymes (JAMMs) (See main text introduction for details).
Figure 4 Verification of screen results.
(a) Three-dimensional scatter plot of screen results. Localisation to DNA damage
sites is divided into three categories on the x-axis (no effect, recruited or excluded).
Immunoblotting screen results were scored based on the numbers of altered
phosphorylation signals (0, 1, 2 and 3). For the DSB repair assay, tail moment ratio is
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plotted on the z-axis. DUBs are coloured based on comet assay DNA repair defects,
as indicated by the bar on the left. (b) Neutral comet assays with two individual
siRNAs targeting indicated DUBs. Data show the means of two (DUB depletions) or
three (control siRNA) biologically independent experiments respectively. The blue
line indicates two times standard deviation of siRNA control. DUBs that scored
positive in all three screens are shown in blue. (c) Clonogenic survival assays with
individual siRNAs targeting top hit DUBs from the screen. Data represent the
individual results of two biologically independent experiments (solid lines and dashed
lines).
Figure 5 UCHL5 promotes HR repair.
(a) Left: Clonogenic survival assays with IR. Depletions of XRCC4 (siXRCC4) and
BRCA1 (siBRCA1) are positive controls. Data show the means of four biologically
independent experiments. The error bars indicate standard error of means. Right:
Depletion efficiency of UCHL5 with siRNAs targeting the coding sequence (#1 and
#2) or 3’UTR. Tubulin is shown as a loading control. (b, c) U2OS cells or U2OS cells
carrying a direct repeat-GFP reporter transfected with the indicated siRNAs were
processed for NHEJ (b) or HR (c) repair assays; Ligase IV depletion (siLigIV) and
CtIP depletion (siCtIP) are respective positive controls. Data show the means of two
(b) or three (c) biologically independent experiments, respectively. p-values are
indicated by asterisks (**; p < 0.005, ***; p < 0.001). The error bars indicate standard
error of means. (d) GFP or GFP-UCHL5 (wild-type: WT or deubiquitylase dead: DD)
expressing U2OS cells transfected with the indicated siRNAs were processed for
neutral comet assays. Data represent the means of two biologically independent
experiments. (e) U2OS cells stably expressing RFP-53BP1 were transiently
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transfected with GFP-UCHL5 (WT or DD) and subjected to laser micro-irradiation.
Images were taken before (undamaged: UD) or 15 min after irradiation (damaged: D).
Localisation of endogenous UCHL5 to site of DNA damage was not examined due to
lack of a suitable antibody. Arrows indicate irradiated areas. Scale bar indicates 10
m.
Figure 6 UCHL5 contributes to resection by regulating EXO1 recruitment.
(a, b, c) Cells transfected with indicated siRNAs were treated with camptothecin
(CPT, 1 M, 1 h) then subjected to immunoblotting with indicated antibodies (a),
quantitative resection assay with anti-BrdU antibody (the means of three biologically
independent experiments with standard errors of means, * means p < 0.05) (b), or
anti-RPA antibody (data represent the means of two biologically independent
experiments) (c). (d, e) GFP or GFP-UCHL5 (WT or DD) expressing U2OS cells
transfected with indicated siRNAs were treated or mock treated with 1 M of CPT for
1 h and analyzed by immunoblotting as indicated. (f) Intensity of GFP-CtIP at DNA
damage sites relative to the unirradiated area was quantified 15 min after irradiation.
Data show the means of three biologically independent experiments with error bars
indicating standard errors of means. (g) Kinetics of GFP-EXO1 accumulation at DNA
damage sites was assessed in cells transfected with indicated siRNAs. Signal intensity
of GFP-EXO1 at DNA damage sites relative to the unirradiated area was quantified.
Data show the means of three biologically independent experiments with error bars
indicating standard errors of means.
Figure 7 UCHL5 regulates resection by protecting NFRKB from proteasomal
degradation.
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(a) Cells transfected with indicated siRNAs were processed for immunoblotting with
indicated antibodies. Arrow indicates position of NFRKB. (b) Left: Cells transfected
with indicated siRNAs were incubated with 100 μg/ml of cycloheximide (CHX) for
various times and processed for immunoblotting with indicated antibodies. Right:
Quantification of data shown on left. Data show the means of two biologically
independent experiments. (c) GFP or GFP-UCHL5 expressing cells transfected with
indicated siRNAs were analyzed by immunoblotting as indicated. (d) GFP and GFP-
NFRKB expressing cells were mock transfected or transiently transfected with an
expression plasmid of HA-tagged ubiquitin (HA-Ub). Chromatin fractions were
immunoprecipited with an anti-GFP antibody followed by immunoblotting. Brackets
indicate ubiquitylated NFRKB. For inputs, see Supplementary Fig. 3f. (e) GFP or
GFP-NFRKB stably expressing cells transfected with indicated siRNAs were
subjected to quantitative resection assays. Data show the means of two biologically
independent experiments. (f) Modified “traffic light reporter system” based HR assay
with indicated siRNAs. Data show the means of two biologically independent
experiments. (g) U2OS cells transfected with indicated siRNAs were subjected to
clonogenic survival assays after IR. Data show the means of two biologically
independent experiments. (h) Cells transfected with individual or indicated
combinations of siRNAs were processed for quantitative resection assays. Data show
the means of two biologically independent experiments. (i) U2OS cells transfected
with indicated siRNAs were subjected to quantitative resection assays. Data show the
means of two biologically independent experiments. (j) U2OS cells were incubated
with CHX (100 g/ml) and or MG132 (10 M) for 1 h prior to camptothecin (CPT)
treatment (1 M, 1 h). Nucleoplasmic fractions were subjected to immunoblotting
with indicated antibodies. Relative protein levels of NFRKB are indicated with
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normalization by HDAC1 levels. (k) After incubating GFP or GFP-NFRKB
expressing cells with 10 M MG132, nucloplasmic (Nu) and chromatin (Ch) fraction
were immunoprecipitated with anti-GFP antibody followed by immunoblotting. For
inputs, see Supplementary Fig. 4l.
1METHODS
Cell lines and cell culture
All cell lines were cultured at 37˚C in a 5% CO2 humidified atmosphere. U2OS cell
lines stably expressing GFP
47
, GFP-53BP1, RFP-53BP1
48
, GFP-UCHL5 (WT and
DD), GFP-NFRKB and GFP-CtIP
49
were cultured with Dulbecco’s modified Eagle
medium (DMEM, Sigma-Aldrich) containing 10% fetal bovine serum (FBS, Gibco),
100 U/ml penicillin (Gibco), 100 g/ml streptomycin (Gibco), 292 g/ml L-
Glutamine (Gibco) and 500 g/ml Geneticin (Gibco). U2OS cells were cultured with
identical media without Geneticin. The stable U2OS cell line expressing both GFP-
EXO1 and monomeric version of Kusabira Orange2-fused human Geminin (1-110 a.
a.) (mKO2-hGeminin)
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was cultured with the Geneticin containing media described
above supplemented with 200 g/ml Hygromycin B (Invitrogen). U2OS cells stably
expressing the HR reporter Direct Repeat-GFP and U2OS cells carrying modified
traffic light reporter based HR assay were cultured with DMEM containing FBS,
penicillin, streptomycin, L-Glutamine and 1 g/ml of puromycin (Sigma-Aldrich).
Live cell imaging based screening
U2OS cells stably expressing RFP-53BP1 in 35 mm glass-bottom dishes (WillCo-
dish) were transfected with 1 g of expression plasmids coding each GFP-DUB with
FuGENE 6 and further cultured for 48 hours in the presence of 10 M 5-Bromo-2’-
deoxyuridine (BrdU). On the day of analysis, the media was replaced with phenol red-
free DMEM (Sigma-Aldrich) supplemented with 10% FBS, penicillin, streptomycin
and 25 mM HEPES buffer (pH 7.0-7.6, Sigma-Aldrich). DNA damage was induced
by irradiating cells through a UPlanSApo 60 x /1.35 oil objective lens with UV-A
laser (405 nm) using a IX81 confocal microscope (Olympus) equipped with a 37˚C
2heating stage (Ibidi). The laser output was set at 400 W with 50 scans of 10
msec/pixel. Up to 1 hour after damage induction, images were taken and analyzed by
using FluoView 1000 software (Olympus).
Immunoblotting based screen
U2OS cells were transfected with 30 nM of siRNA control (AllStars Negative
Control, QIAGEN) or an siRNA pool of four siRNAs targeting each DUB (QIAGEN)
over two days using HiPerFect (QIAGEN). Seventy-two hours after the initial siRNA
transfection, the cells were treated with 40 g/ml of phleomycin for 2 hours or mock
treated. After phleomycin removal, the cells were further cultured for 6 hours. For
immunoblotting analysis, cell extracts were prepared with Laemmli buffer [62.5 mM
Tris-HCl (pH 6.8), 10% Glycerol, 2% sodium dodecyl sulfate and 5% -
mercaptoethanol] at each time point and protein concentration of the samples was
determined by measuring absorbance at 280 nm using a NanoDrop (Thermo
Scientific) with bovine serum albumin protein standard (Thermo Scientific).
Neutral comet assay
Seventy-two hours after 30 nM siRNA transfection, the cells were incubated with 40
g/ml phleomycin for 2 hours or mock incubated. Following phleomycin treatment,
cells were washed twice with PBS and cultured for an additional 2 hours. The cells
were subsequently washed twice with PBS (-) (Gibco) and collected by trypsinization.
Approximately 5 x 10
3
cells in 10 l of PBS (-) were mixed with 90 l of LMAgarose
(TREVIGEN), placed on GelBond Film (Lonza), covered with a 22 mm cover slide
(VWR INTERNATIONAL) and left at 4˚C for 1 hour. Upon removal of the cover
slide, the cells were lysed with Lysis Solution (TREVIGEN) at 4˚C for 1 hour.
3Following a wash with TBE [90 mM Tris-Borate (pH 8.3) and 2 mM
ethylenediaminetetraacetic acid (EDTA)], the samples were subjected to
electrophoresis at 35 V, for 7 min in TBE. After washing with TBE, samples were
fixed with 70% ethanol for 5 min at room temperature and dried overnight. The nuclei
were stained with SYBR Green I (Invitrogen) in 10 mM Tris-HCl (pH 7.5) and 1 mM
EDTA for 5 min at 4˚C. Images were taken with a fluorescent microscope IX71
(Olympus) with Cell^F software (Olympus). Tail moments were measured by using
CometScore software (TriTek). The means of tail moment of at least 30 cells or 50
cells were measured per condition for screen with siRNA pools or for the assay with
the individual siRNAs, respectively. Efficiency of DSB repair was determined as the
tail moment ratio between 2 hours after phleomycin removal and immediately after
treatment.
Clonogenic survival assay
Clonogenic viability was examined using a colony formation assay. Briefly, forty-
eight hours after initial transfection with siRNAs, cells were seeded in 6 well plates
and treated with acute IR or various doses of camptothecin for 1 hour on the
following day. Colonies were stained with crystal violet solution [2% crystal violet
(Sigma-Aldrich) in 10% ethanol] 10-13 days after DNA damaging reagent treatment.
NHEJ and HR repair assay
NHEJ and HR repair assay was carried out as previously described
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. Briefly, NHEJ
repair efficiency was examined by random plasmid integration. HR repair efficiency
was investigated by a chromosomal DSB-induced gene-conversion assay system with
transient expression of I-SceI restriction enzyme in U2OS cells carrying Direct-
4Repeat GFP reporter as previously described or in U2OS cells carrying modified
“traffic light reporter system” that was modified from the published protocol
52
(J. V.
F. et al. personal communication).
Immunofluorescent staining
For the purpose of single-strand DNA detection, cells were fixed with methanol for
30 min at -20˚C and subsequently washed once with ice-cold acetone. In all the other
experiments, cells were fixed with 4% paraformaldehyde for 15 min at room
temperature and then permeabilized by incubating with 0.2% Triton X-100 in PBS for
5 min at room temperature. To examine RPA2 foci formation, cells were pre-
extracted prior to fixation with pre-extraction buffer [10 mM Pipes (pH 6.8), 3 mM
MgCl2, 3 mM EDTA, 0.5% Triton X-100, 0.3 M Sucrose and 50 mM NaCl] for 5 min
on ice. Hereafter, samples were washed twice with 0.1% Tween 20 in PBS after each
procedure. After incubating cells with blocking buffer [5% FBS, 0.1% Triton X-100
in PBS] for 30 min, cells were sequentially incubated with primary antibodies for 1
hour and with secondary antibodies for 30 min diluted in blocking buffer. Following
nuclei staining with 1 g/ml of 4',6-diamidino-2-phenylindole (DAPI) solution for 10
min, samples were sealed with VECTASHIELD (Vector) and images were taken as
described above.
Cell extract preparation
Except for the immunoblotting based screen and cellular fractionation, cell extracts
were prepared with CSK buffer [10 mM PIPES (pH 6.8), 3 mM MgCl2, 1 mM
ethylene glycol tetraacetic acid (EGTA), 0.1% Triton X-100, 300 mM sucrose and
300 mM NaCl] containing 1 x protease inhibitor cocktail (Roche), 1 x phosphatase
5inhibitor cocktail (Sigma-Aldrich), 20 mM N-Ethylmaleimide (NEM, Sigma-Aldrich)
and 0.25 mM Phenylmethanesulfonyl fluoride (PMSF, Sigma-Aldrich). Cells were
washed twice with ice-cold PBS and incubated with an appropriate volume of CSK
buffer for 1 hour on ice with occasional mixing. Soluble fractions were collected by
centrifugation at 20,000 x g for 10 min at 4˚C. The residual pellet fraction was
washed twice and resuspended with the same buffer, followed by sonication. For
immunoblotting based screens, after washing with ice-cold PBS, cells were lysed with
Laemmli buffer and boiled for 5 min at 95˚C. For cellular fractionation, cells
collected with ice-cold PBS were incubated on ice for 5 min with hypotonic buffer
[10 mM HEPES (pH 7.4), 10 mM KCl, 2 mM MgCl2, 340 mM sucrose, 10% glycerol
and 0.1% Triton X-100] containing 1 x protease inhibitor cocktail, 1 x phosphatase
inhibitor cocktail, 20 mM NEM and 0.25 mM PMSF. The cytoplasmic fraction was
isolated by low speed centrifugation (1,500 x g, 5 min at 4˚C). The residual pellet was
washed once with hypotonic buffer and resuspended with nuclear extraction buffer
[NEB; 20 mM HEPES (pH 7.4), 2 mM MgCl2, 1 mM EGTA, 25% glycerol, 0.1%
Triton X-100] containing 300 mM NaCl, 1 x protease inhibitor cocktail, 1 x
phosphatase inhibitor cocktail, 20 mM NEM and 0.25 mM PMSF. The nucleoplasm
fraction was obtained by vortexing for 30 min at 4˚C, followed by centrifugation at
20,000 x g for 10 min. The pellet was washed, resuspended with NEB containing 0.3
M NaCl, solubilized by sonication and saved as chromatin fraction. Protein
concentration of cell extracts was determined with the Coomassie Protein Assay
Reagent (Thermo Scientific).
Quantitative DNA-end resection assay
6For direct detection of single-stranded DNA formation in the context of DNA-end
resection, cells were incubated with 30 M of BrdU for 24 hours prior to 1 M of
camptothecin treatment for 1 hour. Following camptothecin treatment, cells were
collected by trypsinization, washed twice with PBS and fixed with 70% ethanol at
-20˚C overnight.  Hereafter cells were washed with 0.1% Tween 20 in PBS between
each procedure. After incubation with blocking buffer (5% FBS, 0.1% Triton X-100
in PBS) for 30 min, cells were incubated for 1 hour with anti-BrdU antibody and anti-
Cyclin A antibody in blocking buffer under non-denaturing condition to detect only
ssDNA with anti-BrdU antibody. The cells were further incubated with anti-rabbit
IgG antibody conjugated with Alexa Fluor® 594 and anti-mouse IgG antibody
conjugated with Alexa Fluor® 488 (Life Technology) in the dark for 30 min. The
cells were suspended in 1 g/ml of DAPI solution and processed with LSRFortessa
(BD Biosciences). RPA loading onto ssDNA generated through DNA-end resection
during HR was quantitatively measured as previously described by using an anti-
Cyclin A antibody instead of an anti-H2AX antibody
53
.  The anti-BrdU or anti-RPA
antibody signal intensities were obtained from a subpopulation of cells that was
positive for anti-Cyclin A antibody staining using FlowJo software (TreeStar). After
subtraction of the camptothecin non-treated background signal, the mean intensity of
the anti-BrdU and anti-RPA antibody staining of each sample was normalized to that
seen immediately after camptothecin treatment with siRNA control.
Immunoprecipitation
Nucleoplasm fractions, chromatin fractions or soluble fractions from cell extracts
prepared with CSK buffer, were immunoprecipitated with an anti-GFP antibody
coupled to agarose beads (GFP-Trap_A, ChromoTek) or anti-HA antibody coupled to
7agarose beads (EZview Red Anti-HA Affinity Gel, Sigma-Aldrich) by rotating
overnight at 4˚C. The beads were washed six times with their respective cell
extraction buffer and bound proteins were eluted by boiling at 95˚C for 10 min with 1
x Laemmli SDS buffer [62.5 mM Tris-HCl (pH 6.8), 2% SDS, 10% Glycerol, 0.002%
Bromophenol blue]. For the detection of ubiquitylated proteins, beads were washed
twice with the buffer used for cell extract preparation, three times with same buffer
containing 500 mM NaCl and once with the original buffer, followed by elution as
described above.
Cell cycle profile analysis
U2OS cells were incubated for 30 min with 10 M of BrdU, harvested by
trypsinization and fixed with 70% ethanol overnight at -20˚C. Hereafter, the samples
were washed twice with PBS containing 0.1% Tween 20. The samples were then
incubated with denaturing solution (5 M HCl and 0.5% Triton X-100) at 37˚C for 20
min and neutralized with 0.1 M Na2B4O7. After blocking buffer incubation, samples
were incubated with anti-BrdU antibody and an Alexa Flour 488 conjugated
secondary antibody. Finally, the samples were incubated with PI buffer [10 g/ml
propidium iodide (PI, Invitrogen), 250 g/ml RNaseA (Invitrogen)] for 20 min at
37˚C and analyzed with LSRFortessa.
In vivo ubiquitylation assay
The HA-tagged ubiquitin expression vector was transiently transfected in appropriate
cell lines. Forty-eight hours after transfection, fractionated cell extracts were prepared
and subjected to immunoprecipitation as described above.
8In vitro deubiquitylation assay
Stable cell lines expressing GFP-NFRKB were transiently transfected with a plasmid
coding HA-tagged ubiquitin and forty-eight hours after transfection 2 mg of
nucleoplasm extracts were prepared as described above. GFP-NFRKB was
immunoprecipitated with anti-GFP antibody conjugated beads in an identical way to
that described in the immunoprecipitation section. Furthermore, the beads were
washed twice with deubiquitylation buffer [50 mM (Tris-HCl, pH 7.5), 100 mM
NaCl, 1 mM DTT, 0.5 mM EDTA, 1 x protease inhibitor cocktail, 1 x phosphatase
inhibitor cocktail and 0.25 mM PMSF]. The deubiquitylation reaction was performed
in a total volume of 50 l deubiquitylation buffer by incubating immunoprecipitated
GFP-NFRKB (approximately 125 g/reaction) with 100 or 200 ng of recombinant
GST-UCHL5 (Abnova) for 1 hour at 37˚C. The reaction was terminated by adding
12.5 l of 4 x SDS sample buffer and subsequent boiling at 95˚C for 10 min. The
supernatant was subjected to immunoblotting analysis.
RT-qPCR
Total mRNA was isolated from U2OS cells transfected with siRNAs by using
RNeasy kit (QIAGEN) and residual genomic DNA was digested with TUROB-DNA
free kit (Life Technologies). Total mRNAs were reverse transcribed into cDNA using
SuperScript III First-Strand Synthesis System (Life Technologies) with an oligo dT
primer. Quantitative PCR was performed using Fast SYBR Green master mix (Life
Technologies) and StepOnePlus Real-Time PCR System (Life Technologies) with
GAPDH targeting primers (5’ GTCAGCCGCATCTTCTTTTG 3’, 5’
GCGCCCAATACGACCAAATC 3’) and NFRKB targeting primers (5’
CATTGCCCGCCATTCCCATC 3’, 5’ CACCACTCGCACCTGAGACA 3’).
9Live cell imaging with laser micro-irradiation
U2OS cells stably expressing GFP-CtIP or both GFP-EXO1 and mKO2-hGeminin
were incubated with 10 M of BrdU for 24 hours prior to laser micro-irradiation. For
quantitative analysis of accumulation to sites of damage, cells were irradiated with
reduced laser output (200 W) to avoid excess generation of single-stranded DNA.
For GFP-EXO1 accumulation kinetics, images were taken every 6 seconds up to 300
seconds after irradiation with the microscope and software as described for live cell
imaging based screening (see previous section). For GFP-CtIP, images were taken 15
minutes after irradiation. Each single experiment contains at least 10 cells and in total
at least 30 cells were analyzed.
Ionizing irradiation
IR was performed with the Faxitron X-ray machine (Faxitron X-ray Corporation).
Antibodies and siRNAs
Antibodies and siRNAs used in this research are summarized in Supplementary Table
2 and 3, respectively.
Statistic and quantitative analysis
All statistic analysis was done by standard student t-test with two-sided. For
quantitative analysis, mean was used as a center value. The experiments shown with
representative images were successfully reproduced at least twice.
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